Clinical drug supply chain services market seen reaching $13.12B by 2030

The clinical drug supply chain services market is projected to grow from $8.94 billion in 2026 to $13.12 billion by 2030, according to The Business Research Company. The report points to rising clinical trial volume, more complex drug formats and wider use of decentralized trials as the main forces behind the expansion.

Why it matters: - Clinical drug supply chain services are becoming more important as trials grow more complex, more global and more tightly regulated. - The market is forecast to expand at a 10.1% CAGR through 2030, signaling sustained demand for specialized logistics, storage and tracking. - Growth in this segment affects how quickly investigational drugs can reach trial sites and patients under compliant conditions.

What happened: - The Business Research Company published its Clinical Drug Supply Chain Services Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035 on June 30, 2026. - The market is projected to rise from $8.13 billion in 2025 to $8.94 billion in 2026, a 9.8% CAGR. - The report forecasts the market will reach $13.12 billion by 2030. - North America led the market in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa. - The release includes a free sample report and the full market report.

The details: - Clinical drug supply chain services cover sourcing, packaging, storage, distribution and tracking of investigational drugs during clinical trials. - These services help ensure trial materials are delivered on time, under compliant conditions and with controlled storage environments. - The market’s historical growth has been driven by globalization of clinical trials, biologic drug complexity, stricter regulatory compliance, growth in contract research organizations and more multi-region studies. - The report links future growth to AI-enabled predictive supply chain optimization, decentralized and hybrid trials, real-time supply chain monitoring, personalized medicine, cell and gene therapy trials and greater automation of clinical logistics. - The report identifies key trends including cold chain optimization for clinical trial logistics, decentralized drug distribution models, real-time shipment tracking in global trials, more outsourcing to clinical supply specialists and more patient-centric investigational drug delivery. - The report says increasing clinical trial volume is a major demand driver. - ClinicalTrials.gov data showed U.S. registered clinical studies increased from about 479,859 in January 2024 to more than 570,636 in December 2024.

Between the lines: - The forecast suggests the supply chain function is shifting from back-office logistics to a more strategic part of clinical development. - The focus on decentralized trials and real-time monitoring reflects a broader move toward more flexible and patient-centered research models. - The pace of U.S. study registrations underscores how pipeline growth can quickly translate into demand for drug handling infrastructure.

What's next: - The market is expected to keep gaining from automation, monitoring technology and trial decentralization through 2030. - Regional competition may intensify as Asia-Pacific grows faster than the mature North American market. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated technology and trend analysis.

The bottom line: - Clinical drug supply chain services are moving into a high-growth phase as trial sponsors need faster, safer and more compliant ways to move investigational drugs around the world.